Business Wire

LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™

Share

LabGenius, a pioneer in the use of machine learning (ML) for antibody engineering, today announced that it has been awarded a highly competitive SMART grant from Innovate UK. Grants from the £25 million fund allow businesses like LabGenius to realize the potential of new ideas by investing in game-changing, commercially viable research and development projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221007005023/en/

To date, LabGenius’ EVA platform has been used to co-optimize mono- and multi-specific single domain antibodies for biochemical and bio functional properties, including stability, potency and selective tumor cell killing. This grant will be used to further expand EVA 's capabilities by accelerating the platform’s ability to optimize antibody-based immune cell engager molecules.

Many existing antibody therapeutics have poor selective cell killing profiles, which can result in on-target, off-tumor effects, and the discontinuation of treatment. Using EVA ' s predictive power, LabGenius is identifying non-intuitive protein designs, which perform well across multiple therapeutically valuable properties, including selective killing.

Commenting on LabGenius’ funding allocation, UKRI Board Member, Lord David Willetts said: “Machine learning presents real promise to transform the way we approach cancer detection and treatment. It is incredibly exciting to see LabGenius focusing its efforts in this area of therapeutic innovation by continuing to advance their immune cell engager lead optimization capability.”

“We’re incredibly proud to have been awarded a SMART grant from Innovate UK” says LabGenius’ CEO and Founder, Dr. James Field. “This funding will help us realize the potential of computational technologies in R&D as we believe that they are the key to accelerating the discovery and development of advanced therapeutics.”

Speaking to the company’s recent success, LabGenius’ Chief Scientific Officer, Dr. Gino Van Heeke said, “Lead optimization is a critical part of the antibody discovery process, and this funding will allow us to further demonstrate our platform’s potential to use machine learning to accelerate the development of molecules with best-in-class properties.”

– end –

About LabGenius
Headquartered in London, LabGenius is a leading machine learning-driven protein engineering company. The company’s core technology platform, EVA™ , enables the rapid discovery of novel therapeutic antibodies. LabGenius’ highly multidisciplinary team brings together the very best minds from the fields of computer science, robotic automation and synthetic biology.

For more information, please visit www.labgeni.us, or connect on Twitter, LinkedIn and Medium.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries, please contact Lucy Shaw at press@labgeni.us
For business development, please contact James Field at partnerships@labgeni.us

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the

TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release

TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu

Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 23:57:00 EET | Press release

VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain

Citi Global Wealth Investments Releases Outlook 2023: Roadmap to Recovery: Portfolios to Anticipate Opportunities8.12.2022 22:07:00 EET | Press release

Citi Global Wealth Investments (CGWI) today released its Wealth Outlook 2023 (Outlook) report, titled Roadmap to Recovery: Portfolios to Anticipate Opportunities. Published twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond. The latest edition’s title reflects the investing journey that CGWI envisions and the steps that investors should consider diversifying their portfolios. In 2023, CGWI predicts the weakest annual global economic growth in forty years outside of the Global Financial Crisis and the COVID shutdowns. The year ahead is likely to see: A shallow US recession and worse in some other places such as the Eurozone A recovery in Chinese growth, by contrast, as pandemic restrictions are relaxed US inflation continuing to ease, ending 2023 at around 3.5% The US Federal Reserve to start cutting interest rates by the second half of the year A 10% drop in global earnings per share Just as 2022’s global market

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom